C12N 2770/24141
Use of virus, viral particle or viral elements as a vector
C12N2770/24141 (Use of virus, viral particle or viral elements as a vector) appears on 70 US grants and 115 published applications in this corpus.
Search patents in C12N- Granted patents
- 70
- Published applications
- 115
- Assignees
- 67
- Inventors
- 196
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 2 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 2 | 5 |
| 2004 | 1 | 4 |
| 2005 | 3 | 5 |
| 2006 | 1 | 4 |
| 2007 | 2 | 1 |
| 2008 | 1 | 2 |
| 2009 | 3 | 1 |
| 2010 | 1 | 8 |
| 2011 | 2 | 5 |
| 2012 | 1 | 6 |
| 2013 | 4 | 4 |
| 2014 | 6 | 3 |
| 2015 | 4 | 3 |
| 2016 | 2 | 3 |
| 2017 | 2 | 5 |
| 2018 | 3 | 5 |
| 2019 | 4 | 9 |
| 2020 | 3 | 7 |
| 2021 | 5 | 6 |
| 2022 | 7 | 5 |
| 2023 | 3 | 7 |
| 2024 | 1 | 5 |
| 2025 | 3 | 6 |
| 2026 | 2 | 6 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2770/24143Viral genome or elements thereof as genetic vectorIndexing code59
- C12N 2770/24144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code9
- C12N 2770/24145Special targeting system for viral vectorsIndexing code1
- C12N 2770/24142Virus or viral particle as vehicleIndexing code0
Recent patents
- Lassavirus vaccines24 Feb 2026US 12,558,410 B2Katholieke Universiteit Leuven
- Chimeric filovirus vaccines10 Feb 2026US 12,545,709 B2Katholieke Universiteit Leuven
- Cancer therapy compositions and uses thereof2 Dec 2025US 12,485,163 B2HDT Bio Corp.
- Zika virus constructs and therapeutic compositions thereof18 Nov 2025US 12,473,570 B2The Regents of the University of California
- Compositions and methods for dengue virus chimeric constructions in vaccines7 Jan 2025US 12,186,363 B2Takeda Vaccines, Inc.
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Synthetic mrna lacking a polya tail or having a short adenine homopolymer and methods of use and production thereof6 Aug 2026US 2026/0226462 A1Elixirgen Therapeutics, Inc.
- Dengue vaccine unit dose and administration thereof25 Jun 2026US 2026/0174812 A1Takeda Vaccines, Inc.
- Zikv-based gene delivery system19 Mar 2026US 2026/0078403 A1The Regents of the University of California
- Combination therapy of oncolytic virus drugs for cancer treatment26 Feb 2026US 2026/0053873 A1Sichuan Oncocare Biopharmaceutical, Inc.
Most cited
By later US patents
- Chimeric and/or growth-restricted flaviviruses67US 6,184,024 B2The United States of America as represented by the Department of Health and Human Services · 2001
- Bacterial vectors and methods of use thereof52US 7,390,646 B2The Regents of the University of California · 2008
- Chimeric flavivirus vaccines35US 6,696,281 B1Acambis Inc. · 2004
- Immunodeficiency recombinant poxvirus34US 6,596,279 B1Virogenetics Corporation · 2003
- Recombinant yellow fever virus and method of use thereof30US 6,589,531 B1The Regents of the University of California · 2003